Chardan Capital Raises Palvella Therapeutics Price Target to $110

Investment analysts at Chardan Capital have raised their price target for Palvella Therapeutics (NASDAQ:PVLA) from $73.00 to $110.00, reflecting a potential upside of 41.33% based on the stock’s current price. This adjustment, communicated in a note to investors on Friday, comes alongside a maintained “buy” rating for the stock, indicating a positive outlook from the brokerage.

Several other analysts have weighed in on Palvella Therapeutics in recent weeks. Truist Financial increased their target price from $56.00 to $80.00 and affirmed a “buy” rating in a report dated October 2, 2023. Similarly, Canaccord Genuity Group raised their price objective from $66.00 to $90.00 following a report released on October 9, 2023. In contrast, Weiss Ratings issued a “sell (D-)” rating on October 8, 2023, reflecting a more cautious approach.

In addition, Raymond James Financial set a price target of $54.00 on August 5, 2023, while HC Wainwright significantly increased their target from $95.00 to $190.00 in their latest assessment. Currently, one analyst has rated the stock as a “Strong Buy,” eleven have assigned it a “Buy” rating, and one has issued a “Sell” rating. According to data from MarketBeat, the consensus rating for the stock stands at “Moderate Buy,” with a target price averaging $97.58.

Palvella Therapeutics Reports Earnings Results

Palvella Therapeutics recently announced its earnings results for the quarter ending August 14, 2023. The company reported a loss of ($0.86) per share, which fell short of the consensus estimate of ($0.78) by $0.08. Analysts predict that Palvella will post an earnings per share (EPS) of ($3.69) for the current year, indicating ongoing challenges as the company continues its operations.

Institutional investors have also been active in reshaping their stakes in Palvella Therapeutics. During the third quarter, Federated Hermes Inc. acquired a new position in the company valued at approximately $21.3 million. Vanguard Group Inc. notably increased its holdings by 202%, now owning 494,656 shares worth around $31.0 million after adding 330,847 shares in the last quarter.

Other institutional activities include Millennium Management LLC and Woodline Partners LP, both of which acquired new stakes earlier this year, reflecting a growing interest in the biopharmaceutical sector. Currently, institutional investors hold approximately 40.11% of Palvella Therapeutics’ stock.

Company Overview

Palvella Therapeutics Inc., previously known as Pieris Pharmaceuticals Inc., is a clinical-stage biopharmaceutical company based in Wayne, Pennsylvania. The firm is dedicated to developing and commercializing innovative therapies aimed at treating patients with serious, rare genetic skin diseases.

As Palvella Therapeutics continues to navigate through its financial landscape, the revisions in analysts’ price targets suggest a mix of optimism and caution about the company’s future performance in the evolving biopharmaceutical market.